Wall Street Zen downgraded Nurix Therapeutics (NRIX) from hold to sell on September 5, 2026. The rating change follows a quarterly earnings report that missed analyst expectations.
Nurix reported an adjusted loss of $0.81 per share. This performance missed the consensus estimate of a $0.73 loss.
Quarterly revenue totaled $9.04 million. The result fell significantly below the anticipated $15.29 million.
The broader analyst consensus currently maintains a Moderate Buy rating. The average price target for the stock is $34.21. The report emphasizes execution risks and financial underperformance for the development-stage firm.